ABUS NASDAQ
Credit Risk of going bust: lower than 90% of companies Debt: 0.4% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Arbutus Biopharma Corp would be worth roughly what it owes.
Total debt $3.6M against a stock market value of $832.0M.
Distance to default 13.70 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.6M (short-term plus half of long-term), stock volatility 45.5%; Altman Z'' 13.54. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Warminster, PA 18974
US
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patientsâ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Beardsley Robert A | D-Return | 17,948 | $5.00 | 2026-10-01 |
| Nguyen Tuan | D-Return | 48,081 | $5.00 | 2026-10-01 |
| Sawhney Roger | D-Return | 17,142 | $5.00 | 2026-10-01 |
| Androski Lindsay | D-Return | 24,655 | $5.00 | 2026-10-01 |
| Sawhney Roger | M-Exempt | 52,533 | $3.34 | 2026-09-18 |